Text Size

Impact of Caregiver Depression on Asthma in the Child

This study has been completed.
Sponsor:
Information provided by:
University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier:
NCT00223288
First received: September 15, 2005
Last updated: August 2, 2011
Last verified: August 2011
History of Changes
  Purpose

This study will examine if depression in a primary caregiver is associated with more hospitalization or ER visits in children with asthma. This study will also explore whether treatment for depression in the primary caregivers is associated with improvement in asthma in school-aged children.

Asthma is a very common childhood disorder of airway inflammation. The causes include environmental irritants, cold temperature, and infection in the respiratory tract, and emotional factors can contribute to symptom exacerbation. However, asthma is a disease that can be well controlled if there is proper medication compliance and careful control of environmental conditions.

Data suggests that psychiatric symptoms in the mothers of children with asthma are associated with more asthma related hospitalizations in children. Thus, we want to explore this question further using more specific diagnostic instruments in order to detect what types of symptoms are associated with increased asthma related service utilization. Also, we want to explore if effective treatment of the caregivers' symptoms is associated with decreased hospitalization and emergency room visits for the child.


Condition Intervention Phase
Depressive Disorder, Major
Asthma
 Drug: Lexapro
 Phase 4

Study Type: Observational
Official Title: Caregiver Psychiatric Symptomatology and it's Relationship to Service Utilization by Children With Asthma

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Texas Southwestern Medical Center:

Estimated Enrollment: 175
Study Start Date: March 2003
Study Completion Date: February 2006
Primary Completion Date: February 2006 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Sampling Method:   Non-Probability Sample
Study Population

Primary caregiver of a child currently hospitalized at Children's Medical Center of Dallas for an asthma exacerbation and between the ages of 5 and 16 years old

Criteria

Inclusion Criteria:

  • Primary caregiver of a child currently hospitalized at Children's Medical Center of Dallas for an asthma exacerbation and between the ages of 5 and 16 years old
  • Male and female
  • English or Spanish Speaking
  • Between the ages of 18 and 70 years old
  • Caregivers with major depressive disorder will be offered treatment

Exclusion Criteria:

  • At risk for suicide defined by multiple suicide attempts (greater than or equal to 3 in the past), and/or current suicidal ideation with a well-formed plan or intent
  • Unlikely to attend follow-up appointments
  • Mentally retarded or suffer from other severe cognitive impairment
  • Pregnant or nursing, or women of childbearing age who will not use methods of birth control or abstinence during the study
  • Suffering from a severe or life-threatening medical illness which would make completion of the study unlikely
  • Suffering from treatment refractory depression defined by failing three adequate trials of antidepressants
  • Depression as part of bipolar disorder or schizophrenia or schizoaffective disorder, or current depression secondary to a medication or general medical condition, or with psychotic features
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00223288

Locations
United States, Texas
The University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, United States, 75235
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Investigators
Principal Investigator: E. Sherwood Brown, MD, Ph.D. The University of Texas Southwestern Medical Center at Dallas
  More Information

No publications provided

Responsible Party: Sherwood Brown PI, UT Southwestern Medical Center at Dallas
ClinicalTrials.gov Identifier: NCT00223288     History of Changes
Other Study ID Numbers: MHGP MM12
Study First Received: September 15, 2005
Last Updated: August 2, 2011
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Asthma
Depressive Disorder
Depression
Depressive Disorder, Major
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Mood Disorders
Mental Disorders
 Behavioral Symptoms
Citalopram
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 23, 2013